What Is Tirzepatide?
Tirzepatide (LY3298176) is a synthetic 39-amino-acid dual incretin receptor agonist developed by Eli Lilly. It simultaneously targets the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors, making it the first approved compound in what is now classified as the "twincretin" or dual incretin agonist class. It sits between first-generation GLP-1 monotherapy compounds (semaglutide) and the emerging triple-agonist class (retatrutide, which adds glucagon receptor activity).
GIP is the more abundant incretin in humans and plays a distinct role from GLP-1 in postprandial insulin secretion, adipose tissue metabolism, and brain reward circuits. The hypothesis that co-activating both receptors would produce additive or synergistic metabolic effects has been validated by the SURPASS and SURMOUNT clinical programmes, which collectively represent one of the most comprehensive Phase 3 datasets in metabolic research.
Compound identity at a glanceName: Tirzepatide · INN: LY3298176 · Class: Dual GLP-1/GIP incretin receptor agonist ("twincretin") · Structure: 39-amino-acid synthetic peptide · Half-life: ~5 days · Developer: Eli Lilly · Approved brands: Mounjaro (T2D), Zepbound (obesity)
For the full molecular reference — molecular formula, molecular weight, CAS number and the 39-amino-acid sequence — see the Tirzepatide molecular profile.
Mechanism of Action
Tirzepatide's dual-agonist profile engages two complementary incretin pathways that produce additive metabolic effects exceeding either receptor target alone:
| Receptor | Primary location | Effect in research |
|---|---|---|
| GLP-1R | Pancreas, hypothalamus, brainstem, GI tract | Glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, central satiety signalling |
| GIPR | Pancreas, adipose tissue, brain, bone | Postprandial insulin potentiation, adipocyte lipid metabolism, beta-cell function enhancement, potential nausea attenuation |
The GIP receptor mechanism adds several important dimensions not present in GLP-1 monotherapy. In the central nervous system, brain GIPR activation appears to engage reward and satiety circuits that are distinct from hypothalamic GLP-1R pathways, potentially producing complementary appetite suppression. In adipose tissue, GIPR modulates lipid metabolism in ways that may account for tirzepatide's superior fat mass reduction compared to lean-mass-sparing ratios seen with semaglutide. For a data synthesis of lean mass outcomes across SURMOUNT-1 dose groups, see GLP-1 and lean mass loss: clinical data analysis.
GIP and nausea toleranceA key research hypothesis is that GIPR co-activation attenuates GLP-1-mediated nausea. SURPASS-2 head-to-head data versus semaglutide 1mg showed tirzepatide achieved meaningfully greater weight loss with broadly similar GI adverse event rates — suggesting the GIP component may allow higher effective doses with comparable tolerability.
Key Clinical Research: SURPASS & SURMOUNT Programmes
Tirzepatide has one of the most extensive Phase 3 clinical datasets in the incretin class:
| Trial | Programme | Duration | Primary endpoint | Key result |
|---|---|---|---|---|
| SURPASS-2 | T2D (vs semaglutide 1mg) | 40 weeks | HbA1c reduction | −2.46% HbA1c; weight loss 11.2kg vs 5.7kg |
| SURPASS-3 | T2D (vs insulin degludec) | 52 weeks | HbA1c reduction | −2.37% HbA1c; 12.9kg weight loss |
| SURPASS-4 | T2D high CV risk | 104 weeks | HbA1c + CV safety | Non-inferior to glargine on CV safety |
| SURMOUNT-1 | Obesity (no T2D) | 72 weeks | Body weight reduction | 20.9% mean weight loss (15mg) |
| SURMOUNT-2 | Obesity + T2D | 72 weeks | Weight + HbA1c | 15.7% weight loss; −2.1% HbA1c |
| SURMOUNT-4 | Maintenance | 88 weeks | Weight regain post-discontinuation | 14.8% regain after stopping vs −5.5% continued |
SURMOUNT-1's 20.9% weight loss figure at 72 weeks exceeded the STEP 1 semaglutide result (14.9% at 68 weeks) in a comparable population. At the highest doses, roughly 1 in 3 participants achieved ≥ 25% body weight reduction — an outcome historically associated only with bariatric surgery. SURMOUNT-4 replicated STEP 4's discontinuation finding: weight regain is substantial upon cessation, supporting research into long-term continuous administration models.
Tirzepatide vs Semaglutide: Direct Comparison Data
SURPASS-2 is the only published Phase 3 head-to-head trial comparing tirzepatide directly to semaglutide (at 1mg, not the obesity dose of 2.4mg). Data from SURPASS-2 at 40 weeks:
| Endpoint | Tirzepatide 5mg | Tirzepatide 10mg | Tirzepatide 15mg | Semaglutide 1mg |
|---|---|---|---|---|
| HbA1c reduction | −2.09% | −2.37% | −2.46% | −1.86% |
| Weight loss (kg) | −7.8 kg | −10.3 kg | −11.2 kg | −5.7 kg |
| HbA1c < 7% (target) | 82% | 87% | 85% | 79% |
| HbA1c < 5.7% (normal range) | 32% | 40% | 46% | 20% |
Tirzepatide outperformed semaglutide 1mg across all dose cohorts on both glycaemic and weight outcomes. Researchers should note that semaglutide 1mg is the T2D dose — the obesity dose (2.4mg) was not evaluated head-to-head, and SURMOUNT-1 versus STEP 1 data suggests the weight loss gap narrows but does not close at obesity doses (20.9% vs 14.9%).
For a full three-way comparison including retatrutide, see the GLP-1 Peptides Comparison Guide.
Active Research Areas (2026)
Beyond obesity and T2D, tirzepatide is among the most active compounds in metabolic research as of 2026:
| Research area | Trial / status | Rationale |
|---|---|---|
| Heart failure (HFpEF) | SUMMIT — Phase 3, results published 2024 | 15% reduction in worsening HF events; GLP-1 and GIP both expressed in cardiac tissue |
| Obstructive sleep apnoea | SURMOUNT-OSA — Phase 3, 2024 | 62–63% reduction in apnoea-hypopnoea index; FDA approval granted 2024 |
| NASH / MASH (liver) | SYNERGY-NASH — Phase 2, results expected 2026 | GIP and GLP-1 receptors both expressed in hepatocytes; fat mass reduction hypothesis |
| Chronic kidney disease | SURPASS-CVOT — ongoing | Cardioprotection and weight loss in CKD populations |
| Polycystic ovary syndrome | Multiple Phase 2 trials — ongoing | Insulin sensitisation and weight reduction in PCOS metabolic profile |
Research Reconstitution Protocol
RetaLABS Tirzepatide is supplied as a lyophilised (freeze-dried) powder. Use bacteriostatic water — not sterile water — to extend reconstituted solution stability.
| Vial size | Bacteriostatic water | Concentration | Volume per 5mg dose | Volume per 10mg dose |
|---|---|---|---|---|
| 10mg vial | 2.0 mL | 5 mg/mL | 1.00 mL | — |
| 10mg vial | 4.0 mL | 2.5 mg/mL | 2.00 mL | — |
| 30mg vial | 3.0 mL | 10 mg/mL | 0.50 mL | 1.00 mL |
| 30mg vial | 6.0 mL | 5 mg/mL | 1.00 mL | 2.00 mL |
Protocol: Allow vial to reach room temperature. Wipe stopper with alcohol swab. Inject bacteriostatic water slowly along the glass wall — avoid directing flow onto the lyophilised cake. Gently swirl until fully dissolved. Do not vortex, shake, or sonicate. Inspect for clarity before use.
Storage: Lyophilised vials at −20°C, protected from light. Reconstituted solution at 2–8°C; use within 4–6 weeks. Do not freeze reconstituted solution. Use the RetaLABS reconstitution calculator for custom concentrations.
Adverse Effects Profile (Phase 3 Data)
The following adverse event data is drawn from SURMOUNT-1 Phase 3 trial reporting. All data is provided for research context only:
| Adverse event | Tirzepatide 5mg | Tirzepatide 10mg | Tirzepatide 15mg | Placebo |
|---|---|---|---|---|
| Nausea | 31% | 36% | 39% | 9% |
| Diarrhoea | 19% | 20% | 23% | 10% |
| Vomiting | 13% | 16% | 17% | 3% |
| Constipation | 14% | 15% | 16% | 5% |
| Dyspepsia | 8% | 9% | 9% | 3% |
| Discontinuation (GI) | 3.1% | 3.9% | 5.1% | 0% |
Comparing these figures to the semaglutide STEP 1 data (nausea 44%, vomiting 24%) suggests tirzepatide may have a modestly more favourable GI tolerability profile at equivalent weight-loss doses, consistent with the hypothesis that GIPR co-activation attenuates GLP-1-mediated nausea. However, trial populations, escalation schedules, and definitions differ — direct comparison requires caution.
Frequently Asked Questions
- Is tirzepatide available in Australia for research?
- Pharmaceutical tirzepatide (Mounjaro) received TGA approval for type 2 diabetes in Australia in 2023. Research-grade tirzepatide peptide is available from Australian suppliers including RetaLABS for laboratory research purposes — legally distinct from pharmaceutical supply.
- How does tirzepatide compare to semaglutide?
- In the SURPASS-2 head-to-head trial, tirzepatide 15mg achieved −2.46% HbA1c and 11.2kg weight loss versus semaglutide 1mg's −1.86% and 5.7kg. Across population-level Phase 3 data (not head-to-head), tirzepatide achieved 20.9% weight loss (SURMOUNT-1, 72 weeks) versus semaglutide 14.9% (STEP 1, 68 weeks). The dual GLP-1/GIP mechanism appears to drive superior outcomes.
- What is SURMOUNT-1 and what did it find?
- SURMOUNT-1 (NEJM, 2022) was a 72-week Phase 3 trial of tirzepatide in adults with obesity without T2D. At 15mg/week, mean weight loss was 20.9%, with roughly 1 in 3 participants achieving ≥ 25% body weight reduction. This exceeded semaglutide outcomes and approached bariatric surgery results in some historical comparisons.
- What concentration should tirzepatide be reconstituted to?
- For a 30mg vial, adding 3.0 mL bacteriostatic water gives 10 mg/mL (0.5 mL per 5mg dose) — the standard across the RetaLABS GLP-1 range and the maximum a ~3 mL vial holds; a 20mg vial uses 2.0 mL and a 10mg vial 1.0 mL for the same concentration. Use the RetaLABS reconstitution calculator for custom concentrations.
- What is the difference between tirzepatide and retatrutide?
- Both are Eli Lilly compounds. Tirzepatide is a GLP-1 + GIP dual agonist; retatrutide adds a third receptor target — the glucagon receptor. Retatrutide's Phase 2 data (24.2% weight loss at 48 weeks) exceeded tirzepatide's SURMOUNT-1 outcomes, with the glucagon receptor's thermogenic effects likely contributing. Phase 3 data for retatrutide is pending as of 2026.
- Is tirzepatide approved in Australia?
- Mounjaro (pharmaceutical tirzepatide) received TGA approval for type 2 diabetes in Australia. Therapeutic availability and PBS listing status may have changed — consult the TGA register for current approval status. Research-grade tirzepatide from RetaLABS is for laboratory research use only.
Sourcing & Quality Documentation
RetaLABS Tirzepatide is research-grade and supplied for laboratory research purposes only. It is not intended for human therapeutic use.
For guidance on assessing research peptide supplier quality, see our Research Peptides Sourcing Guide. For the legal and regulatory framework governing research peptides in Australia, see our Research Peptides Legal Guide. A downloadable PDF reference summary is also available: Tirzepatide 2026 Researcher's Reference Guide.
For the class-level side-effect profile comparing tirzepatide with semaglutide and retatrutide across their published trials, see the GLP-1 Side Effects Cross-Compound Comparison.